Mablink Bioscience SAS., Université Claude Bernard Lyon 1 and Centre National de la Recherche Scientifique have patented antibody-drug conjugates consisting of antibodies covalently linked to therapeutic drugs through an enzyme-triggered self-immolative linker reported to be useful for the treatment of cancer.

Orexia Therapeutics Ltd. has divulged 2-(3-ethynylbenzyl)-substituted heterocycle derivatives acting as orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, hypersomnia, insomnia and sleep apnea.

Ono Pharmaceutical Co. Ltd. has disclosed monoacylglycerol lipase ABHD6 inhibitors reported to be useful for the treatment of cancer, pain, neurological, inflammatory, autoimmune and metabolic diseases.

Acerand Therapeutics (USA) Ltd. has discovered new son of sevenless homologue 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer.

Nimbus Saturn Inc. has presented mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer and viral infections.

Blueprint Medicines Corp. has synthesized new diazepanone-fused pyrimidines acting as epidermal growth factor receptor (EGFR) (mutant) and/or HER2 (mutant) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, eczema and psoriasis.

Protagonist Therapeutics Inc. has disclosed hepcidin mimetic conjugates acting as solute carrier family 40 member 1 (SLC40A1, ferroportin) ligands with extended half-life and stability.

Compounds acting as AMP-activated protein kinase (AMPK) activators and prostaglandin G/H synthase 2 (PTGS2; COX2) inhibitors have been reported by Nanjing Shupeng Lifescience to be useful for the treatment of pain and inflammatory disorders, among others.

Shanghai Jemincare Pharmaceuticals Co. Ltd. and Jiangxi Jemincare Group Co. Ltd. have patented compounds reported to be useful for the treatment of fungal infections.

Haisco Pharmaceutical Group Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.